Search Results - "Howson, Patrick A."
-
1
Metabotropic glutamate receptor mGlu2 is resistant to homologous agonist-induced desensitization but undergoes protein kinase C-mediated heterologous desensitization
Published in European journal of pharmacology (15-12-2010)“…To investigate the susceptibility of the group II metabotropic glutamate receptor mGlu2 to agonist-induced desensitization, the receptor was stably expressed…”
Get full text
Journal Article -
2
Non-steric-zipper models for pathogenic α-synuclein conformers
Published in APL bioengineering (01-06-2018)“…Parkinson's disease neurodegenerative brain tissue exhibits two biophysically distinct α-synuclein fiber isoforms—single stranded fibers that appear to be…”
Get full text
Journal Article -
3
Beneficial Effects of Trehalose on Striatal Dopaminergic Deficits in Rodent and Primate Models of Synucleinopathy in Parkinson's Disease
Published in The Journal of pharmacology and experimental therapeutics (01-06-2019)“…Disease modification in Parkinson's disease (PD) is an unmet medical need. In the current study, we evaluated trehalose, a safe and well-tolerated disaccharide…”
Get more information
Journal Article -
4
DPI-289, a novel mixed delta opioid agonist / mu opioid antagonist (DAMA), has L-DOPA-sparing potential in Parkinson's disease
Published in Neuropharmacology (15-03-2018)“…L-DOPA-induced dyskinesia (LID) remains a significant problem in the management of Parkinson's disease (PD). In rodent and macaque models of PD, delta opioid…”
Get full text
Journal Article -
5
The link between mitochondrial complex I and brain-derived neurotrophic factor in SH-SY5Y cells – The potential of JNX1001 as a therapeutic agent
Published in European journal of pharmacology (05-10-2015)“…Mitochondrial complex I, which is the first member of the electron transport chain responsible for producing ATP, can produce reactive oxygen species and…”
Get full text
Journal Article -
6
PYM50028, a novel, orally active, nonpeptide neurotrophic factor inducer, prevents and reverses neuronal damage induced by MPP+ in mesencephalic neurons and by MPTP in a mouse model of Parkinson's disease
Published in The FASEB journal (01-07-2008)“…ABSTRACT Many experimental data support the enhancement of neurotrophic factors as a means to modify neurodegeneration in Parkinson's disease. However, the…”
Get full text
Journal Article -
7
Actions of LY341495 on metabotropic glutamate receptor‐mediated responses in the neonatal rat spinal cord
Published in British journal of pharmacology (01-05-2003)“…The group II metabotropic glutamate (mGlu) receptor antagonist (2S,1′S,2′S)‐2‐(2‐carboxycyclopropyl)‐2‐(9H‐xanthen‐9‐yl)glycine (LY341495) also has activity at…”
Get full text
Journal Article -
8
( S)-3,4-DCPG, a potent and selective mGlu8a receptor agonist, activates metabotropic glutamate receptors on primary afferent terminals in the neonatal rat spinal cord
Published in Neuropharmacology (01-03-2001)“…( S)-3,4-Dicarboxyphenylglycine (DCPG) has been tested on cloned human mGlu1–8 receptors individually expressed in AV12-664 cells co-expressing a rat…”
Get full text
Journal Article -
9
Phenylglycine derivatives as antagonists of group III metabotropic glutamate receptors expressed on neonatal rat primary afferent terminals
Published in British journal of pharmacology (01-08-2003)“…Three novel phenylglycine analogues; (RS)‐α‐methyl‐3‐chloro‐4‐phosphonophenylglycine (UBP1110), (RS)‐α‐methyl‐3‐methoxy‐4‐phosphonophenylglycine (UBP1111) and…”
Get full text
Journal Article -
10
Synthesis of phenylglycine derivatives as potent and selective antagonists of group III metabotropic glutamate receptors
Published in Bioorganic & medicinal chemistry letters (26-03-2001)“…The syntheses of a range of ring and α-substituted 4-phosphonophenylglycines are described. A brief discussion of the antagonist activities of compounds 4– 10…”
Get full text
Journal Article